- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05892900
Transcutaneous Vagus Nerve Stimulation (tVNS) for Borderline Personality Disorder (tVNS-BPD) (tVNS-BPD)
Transcutaneous Vagus Nerve Stimulation (tVNS) to Acutely Reduce Emotional Vulnerability and Improve Emotional Regulation in Borderline Personality Disorder (tVNS-BPD): a Randomized, Single-blind, Sham-controlled Trial
The goal of this clinical trial is to test the efficacy of transcutaneous vagus nerve stimulation (tVNS) in borderline personality disorder. The main question it aims to answer is:
• Is tVNS effective in acutely reducing emotional reactivity in borderline personality disorder?
Participants will be randomized to a single session of tVNS or sham-tVNS while going through an affect-inducing procedure. It will consist of the presentation of one neutral and three negative affect-inducing videos in sequence, each of which is followed by a post-induction period during which participants will rate the quality and intensity of their current self-reported emotions.
Researchers will compare the tVNS and sham tVNS groups to see if there is a difference in the intensity of the self-reported emotions between the groups.
Study Overview
Status
Conditions
Detailed Description
The study will be a randomized, single-blind, sham-controlled trial. The goal of this clinical trial is to test the efficacy of transcutaneous vagus nerve stimulation (tVNS) acutely reduce emotional vulnerability and improve emotional regulation in borderline personality disorder. The main questions it aims to answer are:
- Is tVNS effective in acutely reducing emotional reactivity in borderline personality disorder?
- Is tVNS effective in acutely reducing baseline emotional arousal in borderline personality disorder?
- Is tVNS effective in acutely ease emotional recovery in borderline personality disorder?
- Is tVNS effective in acutely improve emotional regulation in borderline personality disorder?
The participants will be randomized to a single session of tVNS or sham-tVNS while going through an affect induction procedure. It will consist of the presentation of one neutral and three negative affect-evoking 4-minutes-long videos in sequence, each of which is followed by a 4-minutes post-induction period during which participants will rate the quality and intensity of their current self-reported emotions (post-induction ratings) and the perceived effectiveness in managing their emotions during the video presentation. The rating of the current self-reported emotions will be repeated after every post-induction period (recovery ratings).
To test the difference in negative emotional arousal at every stage and the perceived effectiveness in managing emotions between the tVNS and sham tVNS groups, mixed models with individuals as random effects will be used. These models will take into account the repeated measurements of the same individuals at baseline, pre-induction, post-induction, and recovery.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Giuseppe Guerriero, MD, MSc
- Phone Number: +46700823616
- Email: giuseppe.guerriero@vgregion.se
Study Contact Backup
- Name: Steinn Steingrimsson, MD, PhD
- Phone Number: +46722448372
- Email: steinn.steingrimsson@vgregion.se
Study Locations
-
-
Västra Götaland
-
Göteborg, Västra Götaland, Sweden, 41345
- Recruiting
- Giuseppe Guerriero
-
Contact:
- Giuseppe Guerriero, MD, MSc
- Phone Number: +46700823616
- Email: giuseppe.guerriero@vgregion.se
-
Contact:
- Steinn Steingrimsson, MD, PhD
- Phone Number: +46722448372
- Email: steinn.steingrimsson@vgregion.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Swedish-speaking and able to provide informed consent to participate in the study
- Female and between the ages 18 and 50 years old.
- Current DSM-5 (Diagnostic and statistical manual of mental disorder-5) diagnosis of BPD based on the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD)
- Capable (in the Investigator's opinion) and willing to comply with all study requirements.
Exclusion Criteria:
- Any unstable medical and/or neurological condition
- Currently pregnant
- Any significant neurological disorder or condition likely to be associated with increased intracranial pressure or cognitive impairment (e.g., a space occupying brain lesion, a history of stroke, a cerebral aneurysm, a seizure disorder, Parkinson's disease, Huntington's chorea, multiple sclerosis)
- Current diagnosis of delirium, dementia or another cognitive disorder secondary to a general medical condition
- Established diagnosis of a developmental and neuropsychiatric disorder (e.g. Down syndrome, autism-spectrum disorder, ADHD)
- Non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the affect induction procedure, follow and answer the survey instructions and questions)
- Alcohol or substance use disorder (relating to opioids, cocaine, amphetamine or benzodiazepine) currently or within the past 1 month
- Daily treatment with antiepileptics (e.g., carbamazepine, gabapentin, lamotrigine, levetiracetam, pregabalin, sodium valproate, topiramate) or benzodiazepines (last dose over 7 days before the screening)
- Alcohol or substance use disorder (relating to opioids or cocaine) currently or within the past 1 month
- Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
- History or diagnosis of bipolar or chronic psychotic disorder (e.g., schizophrenia, schizoaffective disorder).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transcutaneous vagus nerve stimulation (tVNS)
1 tVNS session of ca 45 minutes The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve |
The electrodes are placed at the left ear concha.
The ear concha is principally innerved by the afferent branch of the vagus nerve
Other Names:
|
Sham Comparator: Sham Transcutaneous vagus nerve stimulation (tVNS)
1 sham tVNS session of ca 45 minutes The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation |
The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in negative emotional arousal from baseline at immediately after affect-induction (post-induction ratings) as assessed by PANAS
Time Frame: Baseline and immediately after every of the four videos.
|
The emotional arousal will be measured through the self-reported ratings of negative emotions on the PANAS (PANAS-N).
The scale uses adjectives that describe mood states rather than discrete emotions and are rated from 1 = very slightly or not at all to 5 = extremely.
|
Baseline and immediately after every of the four videos.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in negative emotional arousal from baseline at prior to affect-induction (pre-induction ratings) as assessed by PANAS
Time Frame: Baseline and 4 minutes after the tVNS/sham tVNS has begun, before the affect induction procedure.
|
The emotional arousal will be measured through the self-reported ratings of negative emotions on the PANAS (PANAS-N).
The scale uses adjectives that describe mood states rather than discrete emotions and are rated from 1 = very slightly or not at all to 5 = extremely.
|
Baseline and 4 minutes after the tVNS/sham tVNS has begun, before the affect induction procedure.
|
Change in negative emotional arousal from immediately after affect-induction at 4 minutes after affect induction (recovery ratings) as assessed by PANAS
Time Frame: Immediately after and at 4 minutes after every of the three affect inducing videos
|
The emotional arousal will be measured through the self-reported ratings of negative emotions on the PANAS (PANAS-N).
The scale uses adjectives that describe mood states rather than discrete emotions and are rated from 1 = very slightly or not at all to 5 = extremely.
|
Immediately after and at 4 minutes after every of the three affect inducing videos
|
Perceived effectiveness in managing emotions (PEME) during affect induction.
Time Frame: Immediately after every of the four videos
|
Participants will be asked during the post-induction period about their perceived effectiveness in managing their emotions (PEME) by asking them to rate "How difficult was it to manage your emotional response to this film clip?" from 1 = not at all to 9 = extremely.
This scale will be interpreted as a subjective difficulty in regulating emotions in response to each video stimulus.
|
Immediately after every of the four videos
|
Collaborators and Investigators
Investigators
- Study Chair: Steinn Steingrimsson, MD, PhD, Sahlgrenska University Hospital, Sweden
Publications and helpful links
General Publications
- Daros AR, Williams GE, Jung S, Turabi M, Uliaszek AA, Ruocco AC. More is not always better: Strategies to regulate negative mood induction in women with borderline personality disorder and depressive and anxiety disorders. Personal Disord. 2018 Nov;9(6):530-542. doi: 10.1037/per0000296. Epub 2018 Jul 12.
- Guerriero G, Wartenberg C, Bernhardsson S, Gunnarsson S, Ioannou M, Liljedahl SI, et al. Efficacy of transcutaneous vagus nerve stimulation as treatment for depression: A systematic review. J Affect Disord Rep. 2021 Dec 1;6:100233. https://doi.org/10.1016/j.jadr.2021.100233
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- tVNS-BPD-001
- SU-971761 (Other Grant/Funding Number: Sahlgrenska University Hospital)
- CIVID:22-10-041068 (Registry Identifier: Swedish Medical Products Agency (Läkemedelsverket))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University of EdinburghRecruitingEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Silvia Elisa Hurtado SantiagoCompletedPersonality Disorder, BorderlineSpain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Universitat Jaume IHospital de la RiberaNot yet recruitingBorderline Personality Disorder (BPD)Spain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
-
Norwegian University of Science and TechnologyCompletedPersonality Disorder, Borderline | Avoidant Personality DisorderNorway
Clinical Trials on Transcutaneous vagus nerve stimulation (tVNS)
-
Northwell HealthCompletedStroke | Hemiparesis | Cerebrovascular Accident (CVA)United States
-
Jessica Beresford-WebbFoundation for Prader-Willi ResearchCompletedPrader-Willi Syndrome | Transcutaneous Vagal Nerve Stimulation (tVNS)
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingMajor Depressive DisorderUnited States
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
University College, LondonCompletedHealthy VolunteersUnited Kingdom
-
Rigshospitalet, DenmarkAalborg University HospitalNot yet recruitingFatigue | Systemic Lupus Erythematosus | Autonomic Dysfunction | Autonomic Neuropathy
-
IRCCS Eugenio MedeaAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; IRCCS...Not yet recruitingCerebral PalsyItaly
-
Charles Ethan Paccione, M.S., M.A.CompletedChronic Widespread Pain | FibromyalgiaNorway
-
Queen Mary University of LondonKing's College LondonWithdrawn
-
Sheffield Teaching Hospitals NHS Foundation TrustNot yet recruitingSubarachnoid Haemorrhage From Cerebral Aneurism RuptureUnited Kingdom